Skip to main content
. 2023 Jul 19;59(7):1333. doi: 10.3390/medicina59071333

Table 3.

Outcome data.

Variables All Patients (n = 120)
Technical success 120 (100%)
Clinical success 111 (92.5%)
Coagulopathy correction within 24 h of TAE 57 (47.5%)
Vascular access site hemostasis
  • -

    Manual compression

  • -

    Vascular closure device
63 (52.5%)
57 (47.5%)
Units of packed red blood cells transfused per patient 1.4 (±1.2)
Rebleeding 9 (7.5%)
Non-target embolization 0 (0%)
Complications 12 (10%)
Vascular access-site complications (VASCs) 6 (5%)
Complications, according to SIR classifications
  • -

    None

  • -

    Minor (grades 1 and 2)

  • -

    Major (grades 3–5)
108 (90%)
12 (10%)
0 (0%)
Complications, according to CIRSE classification
  • -

    None

  • -

    Grade 3
108 (90%)
12 (10%)
Treatment required for complications
  • -

    None

  • -

    Medical

  • -

    Interventional

  • -

    Surgical
108 (90%)
6 (5%)
6 (5%)
0 (0%)
30 day bleeding-related mortality 6 (5%)